Smallpox VIG (Vaccinia Immune Globulin)
Baxter also has a strategic partnership to provide Cangene’s Vaccinia Immune Globulin (C-VIG), a hyperimmune globulin used to treat rare but potentially severe adverse reactions to smallpox vaccination.
Vaccinia Immune Globulin (C-VIG) is a sterile solution of purified gamma globulin containing antibodies to the vaccinia virus.
C-VIG has been recently approved by the FDA. It is licensed for the treatment of postvaccinial complications such as eczema vaccinatum, vaccinia necrosum, severe generalised vaccinia, vaccinia infection of eyes, mouth or other sites.
The European Union Commission recommends access to VIG to supplement smallpox stockpiling programmes. In the US, the Centers for Disease Control and Prevention (CDC) are supplementing their smallpox stockpiling strategy through the stocking of Vaccinia Immune Globulin (C-VIG). Recommended stockpiling is at a rate of 1 dose of C-VIG per 10,000 doses of stockpiled vaccine.